Maky Zanganeh became a billionaire after shares of Summit Therapeutics, where she serves as co-CEO, soared following positive ...
Bob Duggan’s success shows you don’t need a Ph.D., or even a college education, to make money in the complex world of biotech ...
New anecdotal evidence suggests some chemoimmunotherapy treatments may improve pulmonary arterial hypertension symptoms, but the overall evidence remains murky.
Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...
ThePrint on MSN3d
This experimental lung cancer drug outperforms blockbuster medicine Keytruda. But there’s a catchIn head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...
The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...
Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...
The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...
Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...
Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback